Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Lymphocyte Predominant Hodgkin's Disease
NCT00003820Phase 2Completed
- Start
- Jan 1999
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Started Jan 1999; status: completed.
02
Drugs
rituximab
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
Beyond the preview
Go deeper on NCT00003820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003820.